Browsing by Subject "CRISPR-Cas"

Sort by: Order: Results:

Now showing items 1-5 of 5
  • Deptula, Paulina; Laine, Pia K; Roberts, Richard J.; Smolander, Olli-Pekka; Vihinen, Helena; Piironen, Vieno; Paulin, Lars; Jokitalo, Eija; Savijoki, Kirsi; Auvinen, Petri; Varmanen, Pekka (BioMed Central, 2017)
    Abstract Background Propionibacterium freudenreichii is an industrially important bacterium granted the Generally Recognized as Safe (the GRAS) status, due to its long safe use in food bioprocesses. Despite the recognized role in the food industry and in the production of vitamin B12, as well as its documented health-promoting potential, P. freudenreichii remained poorly characterised at the genomic level. At present, only three complete genome sequences are available for the species. Results We used the PacBio RS II sequencing platform to generate complete genomes of 20 P. freudenreichii strains and compared them in detail. Comparative analyses revealed both sequence conservation and genome organisational diversity among the strains. Assembly from long reads resulted in the discovery of additional circular elements: two putative conjugative plasmids and three active, lysogenic bacteriophages. It also permitted characterisation of the CRISPR-Cas systems. The use of the PacBio sequencing platform allowed identification of DNA modifications, which in turn allowed characterisation of the restriction-modification systems together with their recognition motifs. The observed genomic differences suggested strain variation in surface piliation and specific mucus binding, which were validated by experimental studies. The phenotypic characterisation displayed large diversity between the strains in ability to utilise a range of carbohydrates, to grow at unfavourable conditions and to form a biofilm. Conclusion The complete genome sequencing allowed detailed characterisation of the industrially important species, P. freudenreichii by facilitating the discovery of previously unknown features. The results presented here lay a solid foundation for future genetic and functional genomic investigations of this actinobacterial species.
  • Deptula, Paulina; Laine, Pia K.; Roberts, Richard J.; Smolander, Olli-Pekka; Vihinen, Helena; Piironen, Vieno; Paulin, Lars; Jokitalo, Eija; Savijoki, Kirsi; Auvinen, Petri; Varmanen, Pekka (2017)
    Background: Propionibacterium freudenreichii is an industrially important bacterium granted the Generally Recognized as Safe (the GRAS) status, due to its long safe use in food bioprocesses. Despite the recognized role in the food industry and in the production of vitamin B12, as well as its documented health-promoting potential, P. freudenreichii remained poorly characterised at the genomic level. At present, only three complete genome sequences are available for the species. Results: We used the PacBio RS II sequencing platform to generate complete genomes of 20 P. freudenreichii strains and compared them in detail. Comparative analyses revealed both sequence conservation and genome organisational diversity among the strains. Assembly from long reads resulted in the discovery of additional circular elements: two putative conjugative plasmids and three active, lysogenic bacteriophages. It also permitted characterisation of the CRISPR-Cas systems. The use of the PacBio sequencing platform allowed identification of DNA modifications, which in turn allowed characterisation of the restriction-modification systems together with their recognition motifs. The observed genomic differences suggested strain variation in surface piliation and specific mucus binding, which were validated by experimental studies. The phenotypic characterisation displayed large diversity between the strains in ability to utilise a range of carbohydrates, to grow at unfavourable conditions and to form a biofilm. Conclusion: The complete genome sequencing allowed detailed characterisation of the industrially important species, P. freudenreichii by facilitating the discovery of previously unknown features. The results presented here lay a solid foundation for future genetic and functional genomic investigations of this actinobacterial species.
  • Sattar, Muhammad Naeem; Iqbal, Zafar; Al-Khayri, Jameel M.; Jain, Shri Mohan (2021)
    Fruit trees provide essential nutrients to humans by contributing to major agricultural outputs and economic growth globally. However, major constraints to sustainable agricultural productivity are the uncontrolled proliferation of the population, and biotic and abiotic stresses. Tree mutation breeding has been substantially improved using different physical and chemical mutagens. Nonetheless, tree plant breeding has certain crucial bottlenecks including a long life cycle, ploidy level, occurrence of sequence polymorphisms, nature of parthenocarpic fruit development and linkage. Genetic engineering of trees has focused on boosting quality traits such as productivity, wood quality, and resistance to biotic and abiotic stresses. Recent technological advances in genome editing provide a unique opportunity for the genetic improvement of woody plants. This review examines application of the CRISPR-Cas system to reduce disease susceptibility, alter plant architecture, enhance fruit quality, and improve yields. Examples are discussed of the contemporary CRISPR-Cas system to engineer easily scorable PDS genes, modify lignin, and to alter the flowering onset, fertility, tree architecture and certain biotic stresses.
  • Hietanen, Sakari (Helsingin yliopisto, 2022)
    Suuresta tarpeesta huolimatta, ei työvälineitä geeniekspression endogeeniseen säätelyyn ole nykypäivänä tarjolla lääketieteellisiin eikä tutkimuksellisiinkaan tarkoituksiin. Vuonna 2017 karakterisoitiin uuden CRISPR-Cas tyypin VI kompleksit. Nämä kompleksit hyödyntävät endonukleaasiaktiivisuudessaan uudenlaista Cas13 -efektoria, jonka kohteena toimii yksijuosteiset RNA-molekyylit. Cas13 tunnistaa kohteensa opas-RNA:n (gRNA) avulla. Tätä komplementaarisuutta hyödyntämällä on onnistuttu kohdistamaan Cas13:n aktiivisuus spesifisiin lähetti-RNA molekyyleihin nisäkässolukokeissa ilman kohde-RNA:n ulkopuolisia hajoamistuotteita. Tämän lisäksi nukleaasiinaktivoituja Cas13 efektoreita (dCas13) on käytetty esimerkiksi kohdennettuun nukleotidien deaminaatioon ja vaihtoehtoisen silmikoinnin indusointiin. Tämä todistaa dCas13 efektorien kyvyn toimia ohjelmoitavina apuproteiineina, joiden avulla voidaan ohjata kompleksiin liitetyn proteiinin toiminta spesifisille kohde-RNA:n alueille. Tässä tutkimuksessa, kaksi eukaryoottien translaatioon osallistuvaa proteiinia, ELAVL1 ja EIF4E, yhdistettiin dCas13b efektorin kanssa C- ja N-terminaalisesti, tarkoituksena lisätä kohteena olevan lähetti-RNA:n ekspressiota parantamalla tämän translatiivisuutta tai stabiliteettia. Koeasetelmassa vertailtiin näiden neljän fuusioproteiinin sekä aktiivisen Cas13b:n vaikutusta lusiferaasin ekspressioon käyttäen kuutta eri gRNA:ta aktivaation ohjaamisessa. Kokeet suoritettiin in vitro ympäristössä HEK293T-soluissa. Natiivi Cas13b vähensi merkittävästi lusiferaasisignaalia, kun taas samassa asetelmassa C-terminaalinen dCas13b-ELAVL1 fuusio lisäsi tätä tilastollisesti merkittävästi eli aikaansai kasvaneen lusiferaasiekspression. Vastaavaa vaikutusta ei ollut havaittavissa muissa fuusioproteiineissa. Tulokset todistavat onnistuneen Cas13b-välitteisen degradaation, sekä dCas13bELAVL1-välitteisen lisääntyneen lusiferaasitranskriptin translaation. Jatkotutkimusta vaaditaan fuusioproteiinin toiminnallisuuden ja varsinaisen kohteen ulkopuolisen aktiivisuuden määrityksessä. Siitä huolimatta tutkimuksessa esitelty fuusoproteiinikonstrukti voisi hyvin olla toimiva työkalu geeniekspression spesifin lisäyksen mahdollistamisessa endogeenisessa kontekstissa
  • Vesikansa, Aino (2018)
    The complex structure and highly variable gene expression profile of the brain makes it among the most challenging fields to study in both basic and translational biological research. Most of the brain diseases are multifactorial and despite the rapidly increasing genomic data, molecular pathways and causal links between genes and central nervous system (CNS) diseases are largely unknown. The advent of an easy and flexible CRISPR-Cas genome editing technology has rapidly revolutionized the field of functional genomics and opened unprecedented possibilities to dissect the mechanisms of CNS disease. CRISPR-Cas allows a plenitude of applications for both gene-focused and genome-wide approaches, ranging from original "gene scissors" making permanent modifications in the genome to the regulation of gene expression and epigenetics. CRISPR technology provides a unique opportunity to establish new cellular and animal models of CNS diseases and holds potential for breakthroughs in the CNS research and drug development.